On April 30, 2024, Sarah Butler, chief commercial officer of ADVI Health, Lindsay Bealor Greenleaf, solution leader for Federal and State Policy at ADVI Health, Hillary Cavanagh, senior director at PhRMA, and Lyn Fitzgerald, chief growth officer, at Ontada hosted a panel presentation at Asembia AXS24 on “Election Policy Issues and the Patient Journey Ripple Effect: IRA, The War on Cancer.”

In this panel discussion, they discussed the major healthcare issues impacting the 2024 Election, the big innovation and drug development issues tied to the drug pricing provisions of the Inflation Reduction Act, Part D Redesign, and their potential implications for patients, providers, and payers.

Hear more from Sarah and Lindsay as they sheds light on key insights from the panel discussion as well as takeaways from Asembia’s AXS24 Summit.

Learn More

ADVI experts will continue to analyze trends throughout the implementation of the Inflation Reduction Act (IRA) and the 2024 presidential election. Get in touch today to gain expert insights on the IRA and the evolving healthcare landscape.